SunTrust Robinson Humphrey's biotech team views the acquisition of Celgene, which follows December’s acquisition of TESARO, by large pharma as ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE